{
  "docId": "019de077-0326-7579-845c-ff13347b3147",
  "docSlug": "a6759fd47798a8f3f6e744ad8917865e",
  "documentTitle": "Exscientia | Investor Presentation Deck | 93 slides",
  "authorId": "exscientia",
  "authorName": "Exscientia",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 78,
  "pageCount": 93,
  "prevPage": 77,
  "nextPage": 79,
  "slideType": "solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a two-column layout to contrast PK and Toxicology findings.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-0326-7579-845c-ff13347b3147/78",
  "deckHref": "/decks/019de077-0326-7579-845c-ff13347b3147",
  "deckJsonHref": "/decks/019de077-0326-7579-845c-ff13347b3147.json",
  "deckAnchorHref": "/decks/019de077-0326-7579-845c-ff13347b3147#slide-78",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.39,
        "x": 0.524,
        "y": 0.325
      },
      "kind": "list",
      "text": "Toxicology & Safety Pharmacology: No unexpected in vitro or in vivo safety concerns identified, No changes recorded in dog CV telemetry study, Tolerated in rat/dog 28-day GLP tox studies, Margins suitable for progression to clinical trial",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8b7b5749-e341-4469-a7d2-27811defe79f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.39,
        "x": 0.086,
        "y": 0.325
      },
      "kind": "list",
      "text": "Pharmacokinetics (PK): Good preclinical PK profile, High oral bioavailability, Human PK predicted to be suitable for once-a-day administration, Predicted human half-life should provide benefits to on-target tox management, Brain penetration demonstrated",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9386ea12-f053-43cb-b91f-7901f4826559",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.735,
        "x": 0.076,
        "y": 0.145
      },
      "kind": "title",
      "text": "Favourable PK, tox and safety profile supports ongoing development",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2b8443fb-b76a-4070-95b3-45251ddb43f8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.085,
        "x": 0.076,
        "y": 0.065
      },
      "kind": "title",
      "text": "LSD1",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cf8f39b4-be26-451b-89b0-89943da85312",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}